Trefoil Therapeutics, co-founded by FSU College of Medicine Professor Michael Blaber, is beginning its first clinical trial using regenerative treatment for patients with corneal endothelial dystrophies. The therapy uses technology developed by Blaber and licensed by FSU.
Click here to read more, or visit www.trefoiltherapeutics.net.